Boule Diagnostics publishes Q3 2026 earnings presentation

• Boule Diagnostics’ third-quarter 2026 sales fell 24.4% to SEK 96.2 million; organic sales declined 19.4%.
• Adjusted operating loss reached SEK 4.5 million versus a SEK 12 million profit; gross margin held at 41.1% versus 41.2%.
• Diagnostics sales dropped 30%, primarily reflecting supply-chain disruptions to 3-part instrument deliveries; demand for 5-part human and veterinary instruments was weak.
• OEM sales declined 6% to SEK 31.5 million; adjusted operating margin improved to 24.6% from 19.3%.
• Operating cash flow rose to SEK 6.9 million from SEK 1 million; available liquidity totaled SEK 21.6 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Boule Diagnostics AB published the original content used to generate this news brief on October 28, 2026, and is solely responsible for the information contained therein.